NORMAN CHAZIN: Open Payments
NPI 1710970553 · LINWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$709 in 30 payments from 7 companies in 2025. Trend: 2023 $642 · 2024 $825 · 2025 $709
Food & beverage: $709
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $254 |
| E.R. Squibb & Sons, L.L.C. | 5 | $180 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| Lundbeck LLC | 3 | $48 |
| Alkermes, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: VRAYLAR, COBENFY, REXULTI, CAPLYTA, ABILIFY ASIMTUFII, Auvelity, LYBALVI, ARISTADA.
Industry payments across NJ — which companies pay providers there.
